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Pulmonary  arterial  hypertension  (PAH)  secondary  to  chronic  obstructive  pulmonary  disease  (COPD)  is  incurable  and  it 
has  an  unpredictable  survival  rate.  Two  men  who  suffered  from  COPD  presented  with  progressive  dyspnea  and  edema, 
respectively.  PAH,  as  estimated  by  the  peak  velocity  of  tricuspidal  regurgitation,  and  the  depressed  myocardial  performance 
index  (MPI)  of  the  right  ventricle  (RV)  were  noted  on  echocardiography.  In  addition  to  the  baseline  therapy  for  their 
depressed  ventilatory  function,  we  prescribed  tadalafil  10  mg  orally  every  other  day  for  2  weeks  and  then  we  doubled  the 
dosage.  They  well  tolerated  the  medication  without  any  notable  side  effects.  After  4  weeks  of  tadalafil  treatment,  the 
patients'  pulmonary  arterial  pressure  was  decreased  and  the  MPI  of  the  RV  was  improved  in  both.  The  exercise  capacity, 
as  measured  by  the  respiratory  oxygen  uptake,  also  improved  from  10.9  mL/kg/min  to  13.8  mL/kg/min  in  one  patient.
We  report  here  on  2  patients  with  PAH  secondary  to  COPD,  and  they  showed  notable  improvement  of  their  pulmonary 
hemodynamics  and  exercise  capacity  with  the  administration  of  tadalafil.
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INTRODUCTION
Pulmonary  arterial  hypertension  secondary  to  chronic  obstructive 
pulmonary  disease  (COPD)  is  incurable  with  an  unpredictable 
survival  rate.  An  oral  administration  of  phosphodiesterase-5 
(PED-5)  inhibitor,  sildenafil,  has  been  regarded  as  a  safe  and 
effective  treatment  for  patients  suffering  with  pulmonary  arterial 
hypertension  (PAH)
1, 2).  However,  its  effects  have  been  transient 
in  nature  due  to  its  short  half  life
1-3).  Tadalafil  is  a  new, 
long-acting  PED-5  inhibitor
3, 4),  and  it  seems  to  be  effective  for 
lowering  the  pulmonary  vascular  resistance
3).  In  this  report  two 
patients  with  pulmonary  arterial  hypertension  secondary  to 
COPD  showed  notable  improvement  in  their  pulmonary 
hemodynamics  and  exercise  capacity  with  the  administration  of 
tadalafil. 
CASE REPORT
Case  1
A  55-year-old  male,  who  was  diagnosed  with  emphysema  5 
years  earlier,  had  complaints  of  progressive  dyspnea  (New  York 
Heart  Association  Class  III)  and  cough  during  his  regular  visits  to 
an  outpatient  clinic.  In  addition  to  the  inhalant  anticholinergics,  he 
had  taken  a  long  acting  beta-agonist  and  theophylline  for  his 
depressed  ventilatory  function  (GOLD  stage  III).  Despite  a  gradual 
exacerbation  of  dyspnea  and  an  increase  in  the  amount  of 
sputum,  there  were  no  signs  of  other  illnesses,  including  fever, 
myalgia  or  sore  throat.  His  blood  pressure  was  135/80  mmHg,  the 
pulse  was  80  beats/min,  the  respiratory  rate  was  20  breaths/min 
and  his  temperature  was  36.5℃.  Electrocardiography  showed  right 
ventricular  hypertrophy,  and  the  chest  X-rays  showed  no  signs  of The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  1,  March  2007 38
Admission Convetional  therapy Tadalafil  10  mg Tadalafil  20  mg
Case  1
TR  grade
TR  Vmax  (m/sec)
MPI  of  RV
trivial
3.7
0.56
trivial
3.8
0.59
trivial
3.3
0.46
trivial
3.2
0.42
Case  2
TR  grade
TR  Vmax  (m/sec)
MPI  of  RV
severe
4.1
0.89
severe
4.0
0.86
severe
3.8
0.60
severe
3.7
0.60
TR,  tricuspidal  regurgitation;  MPI,  myocardial  performance  index;  RV,  right  ventricle 
Table  1.  Echocardiographic  data
pneumonia.  The  forced  expiratory  volume  in  1  second  (FEV1)  was 
30%  of  the  predicted  value,  and  this  had  progressively  worsened 
over  the  preceding  year.  Pulmonary  arterial  hypertension  was 
noted  on  Doppler  echocardiography  with  trivial  tricuspidal 
regurgitation  and  a  peak  velocity  (TR  Vmax)  of  3.6  m/s.  The 
myocardial  performance  index  (MPI)  of  the  right  ventricle  (RV)  was 
0.56,  which  was  not  changed  after  2  weeks  of  treatment.  In 
addition  to  the  baseline  therapy,  we  administered  tadalafil  10  mg 
orally  every  other  day  with  the  patient's  informed  consent.  He  well 
tolerated  a  2  weeks  course  of  this  therapy,  and  he  only 
complained  of  mild  myalgia.  Therefore,  the  tadalafil  was  increased 
up  to  20  mg/every  other  day.  After  4  weeks  of  tadalafil  treatment, 
the  TR  Vmax  was  decreased  to  3.2  m/sec  and  the  MPI  of  the  RV 
was  improved  to  0.42  (Table  1).  His  exercise  capacity,  as 
measured  by  the  respiratory  oxygen  uptake,  also  improved  from 
10.9  mL/kg/min  to  13.8  mL/kg/min.   
Case  2
A  62-year-old  male  presented  with  edema  in  his  legs.  He  had 
been  suffering  from  cor  pulmonale  associated  with  emphysema  for 
2  years.  The  latest  data  collected  from  the  patient's  visit  to  the 
clinic  showed  his  ventilatory  function  being  in  GOLD  stage  IV.  He 
was  tachypneic  (26  breaths/min)  and  had  3  +  pitting  edema  of  the 
legs.  The  patient's  blood  pressure  was  120/75  mm  Hg  and  his 
pulse  was  105  beats/min.  There  were  no  notable  exacerbating 
factors  such  as  pneumonia,  arrhythmia,  pulmonary  arterial 
embolism,  etc.  His  arterial  blood  gas  values  were  a  PO2  of  53  mm 
Hg  and  a  PCO2  of  68  mmHg.  Echocardiography  showed  dilated 
right  chambers  with  severe  tricuspidal  regurgitation.  The  estimated 
TR  Vmax  was  4.1  m/sec  and  the  MPI  of  the  RV  was  0.89. 
Although  the  patient's  edema  substantially  improved  after  therapy 
with  digitalis,  diuretics,  vasodilator  and  bronchodilator,  the  degree 
of  pulmonary  arterial  hypertension  did  not  change.  Therefore, 
tadalafil  therapy  was  attempted  with  the  patient's  written  informed 
consent.  We  prescribed  10  mg  of  tadalafil  orally  every  other  day 
for  2  weeks  and  then  we  doubled  the  dosage.  During  4  weeks  of 
therapy,  he  complained  of  headache  and  mild  orthostatic 
dizziness.  Physical  examination  showed  a  blood  pressure  of 
110/70
  mmHg  and  the  rest  of  the  examination  was  unremarkable. 
Subjective  improvement  in  his  functional  status  was  also  noted 
(New  York  Heart  Association  Class  II).  The  arterial  PO2  was  65 
mmHg  without  inspired  oxygen.  His  TR  Vmax  was  also  decreased 
to  3.7  m/sec  and  the  MPI  of  the  RV  was  improved  to  0.6  (Table  1).
DISCUSSION 
Our  attempt  of  using  tadalafil  showed  promising  results  for 
treating  pulmonary  arterial  hypertension  secondary  to  COPD.  It 
was  safe  and  efficacious  in  improving  the  functional  capacity  and 
pulmonary  hemodynamics.  These  results  were  consistent  with  an 
earlier  report;  in  that  report,  tadalafil  was  administered  to  a  patient 
with  end-stage  primary  pulmonary  arterial  hypertension
5). 
Hypoxia-induced  pulmonary  hypertension  complicates
  the 
course  of
  COPD.  Although  continuous
  oxygen  administration  is 
the  most  reasonable  treatment  for  this  condition,  and  particularly 
when  exercise  tolerance  is  present,  it  has  little  effect
  on  the 
pulmonary  artery  pressure.  A  growing  number  of  studies  in  recent 
years  have  demonstrated  the  promising  efficacy  of  sildenafil  for 
the  treatment  of  pulmonary  arterial  hypertension
1-3).  However,  one 
limitation  is  that  it  requires  frequent  daily  administrations  due  to  its 
short  half-life  of  about  4  hours
1-3).  Tadalafil  is  a  long-acting 
PDE-5  inhibitor  that  has  an  extended  half-life  of  17.5  hours.  It 
appears  to  be  generally  safe  and  well  tolerated  by  patients,  and  it 
has  a  similar  side-effect  profile  to  that  of  sildenafil
3, 4). 
In  summary,  the  present  report  provides  a  valuable  boost  for 
extending  the  use  of  tadalafil  to  the  treatment  of  pulmonary  arterial 
hypertension  secondary  to  COPD,  and  the  results  of  this  treatment 
should  be  quite  favorable.
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